Vitrolife AB (publ)
VTRLY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.48 | 0.00 | -34.25 | 14.41 |
| FCF Yield | 3.23% | 3.52% | 2.01% | 0.52% |
| EV / EBITDA | 25.06 | -6.06 | 29.59 | 109.29 |
| Quality | ||||
| ROIC | 3.53% | -23.39% | 2.39% | 1.72% |
| Gross Margin | 59.27% | 56.32% | 55.04% | 62.24% |
| Cash Conversion Ratio | 1.35 | -0.20 | 1.18 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.72% | 27.84% | 37.44% | 4.33% |
| Free Cash Flow Growth | 42.16% | 16.21% | 70.57% | -4.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.82 | -0.38 | 1.69 | 3.20 |
| Interest Coverage | 7.99 | -38.18 | 14.86 | 43.54 |
| Efficiency | ||||
| Inventory Turnover | 3.48 | 3.71 | 3.59 | 2.03 |
| Cash Conversion Cycle | 131.95 | 109.86 | 107.47 | 165.36 |